Cytokine gene transfer in cancer therapy

6

Kotin

RM

,

Siniscalco

M.

,

Samulski

RJ

et al.

Site-specific integration by adeno-associated virus

.

Proc Natl Acad Sci USA

1990

;

87

:

2211

–

2215

.

7

Berkner

KL

Development of adenovirus vectors for the expression of heterologous genes

.

Biothechniques

1988

;

6

:

616

–

629

.

8

Yang

Y.

,

Li

Q.

,

Ertl

HC

et al.

Cellular and humoral immune responses to viral antigens create barriers to lung-directed gene therapy with recombinant adenoviruses

.

J Virol

1995

;

69

:

2004

–

2015

.

9

Veelken

H.

,

Jesuiter

H.

,

Mackensen

A.

et al.

Primary fibroblasts from human adults as targets cells for ex vivo transfection and gene therapy

.

Hum Gene Ther

1994

;

5

:

1205

–

1212

.

Crossref

10

Liu

Y.

,

Liggitt

D.

,

Zhong

W.

et al.

Cationic liposome-mediated intravenous gene delivery

.

J Biol Chem

1995

;

270

:

24864

–

24870

.

11

Nabel

GJ

,

Gordon

D.

,

Bishop

K.

et al.

Immune response in human melanoma after transfer of an allogeneic class I major histocompatibility complex gene with DNA-liposome complexes

.

Proc Natl Acad Sci USA

1996

;

93

:

15388

–

15393

.

12

Brenner

MK

,

Rill

DR

,

Moen

RC

et al.

Gene marking to trace origin of relapse after autologous bone marrow transplantation

.

Lancet

1993

;

341

:

85

–

86

.

13

Dunbar

CE

,

Cottler-Fox

M.

,

O'Shaughnessy

JA

et al.

Retrovirally marked CD34-enriched peripheral blood and bone marrow cells contribute to long-term engraftment after autologous transplantation

.

Blood

1995

;

11

:

3048

–

3057

.

14

Cohen

MC

,

Cohen

S.

Cytokine function: a study in biologic diversity

.

Am J Clin Pathol

1996

;

105

:

589

–

598

.

15

Bast

RC

, Jr. Principles of cancer biology: tumor immunology.In:

DeVita

VT

,

Hellman

S.

Jr,

Rosenberg

SA

, eds.

Cancer Principles and Practice of Oncology

.

Philadelphia, PA

:

JB Lippincott

,

1985

:

125

–

150

.

Google Preview

16

Wheelock

EF.

An overview of mechanisms responsible for tumor dormancy.In:

Wheelock

EF

, ed.

Cellular Immune Mechanisms and Tumor Dormancy

.

Boca Raton

:

CRC Press

,

1992

:

1

–

13

.

Google Preview

17

Allison

JP

,

Hurwitz

AA

,

Leach

DR.

Manipulation of costimulatory signals to enhance antitumor T-cell responses

.

Curr Opin Immunol

1995

;

7

:

682

–

686

.

18

Cayeux

S.

,

Beck

C.

,

Aicher

A.

et al.

Tumor cells cotransfected with interleukin-7 and B7.1 genes induce CD25 and CD28 on tumor-infiltrating T lymphocytes and are strong vaccines

.

Eur J Immunol

1995

;

25

:

2325

–

2331

.

19

Fenton

RT

,

Sznol

M.

,

Luster

DG

et al.

A phase I trial of B7-transfected or parental lethally irradiated allogeneic melanoma cell lines to induce cell-mediated immunity against tumor-associated antigen presented by HLA-A2 or HLA-A1 in patients with stage IV melanoma

.

Hum Gene Ther

1995

;

6

:

87

–

106

.

20

Fearon

ER

,

Pardoll

DM

,

Itaya

T.

et al.

Interleukin - 2 production by tumor cells bypasses T helper function in the generation of an antitumor response

.

Cell

1990

;

60

:

397

–

403

.

21

Golumbek

PT

,

Lazenby

AJ

,

Levitzky

HI

et al.

Treatment of established renal cancer engineered to secrete interleukin-4

.

Science

1991

;

254

:

713

–

716

.

22

Rosenberg

SA

,

Lotze

MT

,

Yang

JC

et al.

Experience with the use of high-dose interleukin-2 in the treatment of 652 cancer patients

.

Ann Surg

1989

;

210

:

474

–

484

.

23

Veelken

H.

,

Rosenthal

FM

,

Schneller

F.

et al.

Combination of interleukin-2 and interferon-α in renal cell carcinoma and malignant melanoma: a phase II clinical trial

.

Biotechnol Ther

1992

;

3

:

1

–

14

.

24

Rosenfeld

ME

,

Curiel

DT.

Gene therapy strategies for novel cancer therapeutics

.

Curr Opin Oncol

1996

;

8

:

72

–

77

.

25

Douvdevani

A.

,

Huleihel

M.

,

Zoller

M.

et al.

Reduced tumorigenicity of fibrosarcomas which constitutively generate IL-1α either spontaneously or following IL-1α gene transfer

.

Int J Cancer

1992

;

51

:

822

–

830

.

26

Gansbacher

B.

,

Zier

K.

,

Daniels

B.

et al.

Interleukin 2 gene transfer into tumor cells abrogates tumorigenicity and induces protective immunity

.

J Exp Med

1990

;

172

:

1217

–

1224

.

27

Rosenthal

FM

,

Cronin

K.

,

Bannerji

R.

et al.

Augmentation of antitumor immunity by tumor cells transduced with a retroviral vector carrying the interleukin-2 and interferon gamma cDNA

.

Blood

1994

;

83

:

1289

–

1298

.

28

Mullen

CA

,

Coale

MM

,

Levy

AT

et al.

Fibrosarcoma cells transduced with the IL-6 gene exhibit reduced tumorigenicity, increased immunogenicity, and decreased metastatic potential

.

Cancer Res

1992

;

52

:

6020

–

6024

.

29

Porgador

A.

,

Tzehoval

E.

,

Katz

A.

et al.

Interleukin 6 gene transfection into Lewis lung carcinoma tumor cells suppresses the malignant phenotype and confers immunotherapeutic competence against parental metastatic cells

.

Cancer Res

1992

;

52

:

3679

–

3686

.

30

Ferrantini

M.

,

Proietti

E.

,

Santodonato

L.

et al.

Alpha 1-Interferon gene transfer into metastatic friend leukemia cells abrogated tumorigenicity in immunocompetent mice: antitumor therapy by means of interferon-producing cells

.

Cancer Res

1993

;

53

:

1107

–

1112

.

31

Gansbacher

B.

,

Bannerji

R.

,

Daniels

B.

et al.

Retroviral vector-mediated gamma-interferon gene transfer into tumor cells generates potent and long lasting antitumor immunity

.

Cancer Res

1990

;

50

:

7820

–

7825

.

32

Porgador

A.

,

Bannerji

R.

,

Watanabe

Y.

et al.

Antimetastatic vaccination of tumor-bearing mice with two types of gamma-interferon gene inserted tumor cells

.

J Immunol

1993

;

150

:

1458

–

1463

.

33

Blankenstein

T.

,

Qin

Z.

,

Überla

K.

et al.

Tumor suppression after tumor cell-targeted tumor necrosis factor α gene transfer

.

J Exp Med

1991

;

173

:

1047

–

1052

.

34

Colombo

MP

,

Ferrari

G.

,

Stoppacciaro

A.

et al.

Granulocyte colony-stimulating factor gene transfer suppresses tumorigenicity of a murine adenocarcinoma in vivo

.

J Exp Med

1991

;

173

:

889

–

897

.

35

Dranoff

G.

,

Jaffee

E.

,

Lazenby

A.

et al.

Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity

.

Proc Natl Acad Sci USA

1993

;

90

:

3539

–

3543

.

36

Saito

S.

,

Bannerji

R.

,

Gansbacher

B.

et al.

Immunotherapy of bladder cancer with cytokine gene-modified tumor vaccines

.

Cancer Res

1994

;

54

:

3516

–

3520

.

37

Allione

A.

,

Consalvo

M.

,

Nanni

P.

et al.

Immunizing and curative potential of replicating and nonreplicating murine mammary adenocarcinoma cells engineered with interleukin (IL)-2, IL-4, IL-6, IL-7, IL-10, tumor necrosis factor α, granulocyte-macrophage colony-stimulating factor, and -interferon gene or admixed with conventional adjuvants

.

Cancer Res

1994

;

54

:

6022

–

6026

.

38

Tepper

RI

,

Mule

J.

Experimental and clinical studies of cytokine gene-modified tumor cells

.

Hum Gene Ther

1994

;

5

:

153

–

164

.

39

Torre-Amione

G.

,

Beauchamp

RD

,

Koeppen

et al.

A highly immunogenic tumor transfected with a murine transforming growth factor type betal cDNA escapes immune surveillance

.

Proc Natl Acad Sci USA

1990

;

87

:

1486

–

1490

.

40

Colombo

MP

,

Modesti

A.

,

Parmiani

G.

et al.

Local cytokine availability elicits tumor rejection and systemic immunity through granulocyte-T-lymphocyte cross-talk

.

Cancer Res

1992

;

52

:

4853

–

4857

.

41

Tepper

RI

,

Coffman

RL

,

Leder

P.

An eosinophil-dependent mechanism for the antitumor effect of interleukin-4

.

Science

1992

;

257

:

548

–

551

.

42

Cavallo

F.

,

Giovarell

M.

,

Gulino

A.

et al.

Role of neutrophils and CD4⁺ T lymphocytes in the primary and memory response to nonimmunogenic murine mammary adenocarcinoma made immunogenic by IL-2 gene

.

J Immunol

1992

;

149

:

3627

–

3635

.

43

Schmidt

W.

,

Schweighoffer

T.

,

Herbst

E.

et al.

Cancer vaccines: the interleukin 2 dosage effect

.

Proc Natl Acad Sci USA

1995

;

92

:

4711

–

4714

.

44

Connor

J.

,

Bannerji

R.

,

Saito

S.

et al.

Regression of bladder tumors in mice treated with interleukin 2 gene-modified tumor cells

.

J Exp Med

1993

;

177

:

1127

–

1134

.

45

Cao

X.

,

Zhang

W.

,

Gu

S.

et al.

Induction of antitumor immunity and treatment of preestablished tumor by interleukin-6-gene-transfected melanoma cells combined with low-dose interleukin-2

.

J Cancer Res Clin Oncol

1995

;

121

:

721

–

728

.

46

Porgador

A.

,

Tzehoval

E.

,

Vadai

E.

et al.

Combined vaccination with major histocompatibility class I and interleukin 2 gene-transduced melanoma cells synergizes the cure of postsurgical established lung metastases

.

Cancer Res

1995

;

55

:

4941

–

4949

.

47

Zitvogel

L.

,

Tahara

H.

,

Robbins

P.

et al.

Cancer immunotherapy of established tumors with IL-12: effective delivery by genetically engineered fibroblasts

.

J Immunol

1995

;

155

:

1393

–

1403

.

48

Yu

JS

,

Burwick

JA

,

Dranoff

G.

et al.

Gene therapy for metastatic brain tumors by vaccination with granulocyte-macrophage colony-stimulating factor-transduced tumor cells

.

Hum Gene Ther

1997

;

8

:

1065

–

1072

.

49

Gilboa

E.

Immunotherapy of cancer with genetically modified tumor vaccines

.

Semin Oncol

1996

;

23

:

101

–

107

.

50

Rosenthal

FM

,

Zier

KS

,

Gansbacher

B.

Human tumor vaccines: genetic engineering of tumors with cytokine and histocompatibility genes to enhance immunogenicity

.

Curr Opin Oncol

1994

;

6

:

611

–

615

.

51

Sartor

WM

,

Kyprianou

N.

,

Fabian

DF

et al.

Enhanced expression of ICAM-1 in a murine fibrosarcoma reduces tumor growth rate

.

J Surg Res

1995

;

59

:

66

–

74

.

52

Bannerji

R.

,

Arroyo

CD

,

Cordon-Cardo

C.

et al.

The role of IL-2 secreted from genetically modified tumor cells in the establishment of antitumor immunity

.

J Immunol

1994

;

152

:

2324

–

2332

.

53

Huang

AYC

,

Golumbek

P.

,

Ahmadzadeh

M.

et al.

Role of bone marrow-derived cells in presenting MHC Class I-restricted tumor antigens

.

Science

1994

;

264

:

961

–

965

.

54

Parney

IF

,

Petruk

KC

,

Zhang

C.

et al.

Granulocyte-macrophage colony-stimulating factor and B7-2 combination immunogene therapy in an allogeneic Hu-PBL-SCID/Beige mouse-human glioblastoma multiform model

.

Hum Gene Ther

1997

;

8

:

1073

–

1085

.

55

Wie

MX

,

Tamiya

T.

,

Hurford

RK

, Jr et al.

Enhancement of interleukin-4 mediated tumor regression in athymic mice by in situ retroviral gene transfer

.

Hum Gene Ther

1995

;

6

:

437

–

443

.

56

Cordier

L.

,

Duffour

MT

,

Sabourin

JC

et al.

Complete recovery of mice from a pre-established tumor by direct intratumoral delivery of an adenovirus vector harboring the murine IL-2 gene

.

Gene Ther

1995

;

2

:

16

–

21

.

57

Elkins

KL

,

Ennist

DL

,

Winegar

RK

et al.

In vivo delivery of interleukin-4 by a recombinant vaccinia virus prevents tumor development in mice

.

Hum Gene Ther

1994

;

5

:

809

–

820

.

58

Vieweg

J.

,

Boczkowski

D.

,

Roberson

KM

et al.

Efficient gene transfer with adeno-associated virus-based plasmids complexed with cationic liposomes for gene therapy of human prostate cancer

.

Cancer Res

1995

;

55

:

2366

–

2372

.

59

Zatloukal

K.

,

Schneeberger

A.

,

Berger

M.

et al.

Elicitation of a systemic and protective anti-melanoma immune response by an IL-2-based vaccine

.

J Immunol

1995

;

154

:

3406

–

3419

.

60

Sun

WH

,

Burkhoder

JK

,

Sun

J.

et al.

In vivo cytokine gene transfer by gene gun reduces tumor growth in mice

.

Proc Natl Acad Sci USA

1995

;

92

:

2889

–

2893

.

61

Rosenberg

SA.

Immunotherapy and gene therapy of cancer

.

Cancer Res

1991

;

51

:

5074

–

5079

.

62

Rosenberg

SA

,

Aebersold

P.

,

Cornetta

K.

et al.

Gene transfer into humans: immunotherapy of patients with advanced melanoma using tumor infiltrating lymphocytes modified by retroviral gene transduction

.

N Engl J Med

1990

;

323

:

570

–

578

.

63

Rosenberg

SA.

TNF/TIL human gene therapy clinical protocol

.

Hum Gene Ther

1990

;

1

:

443

–

462

.

Crossref

64

Cournoyer

D.

,

Caskey

CT.

Gene transfer into humans: a first step

.

N Engl J Med

1990

;

323

:

601

–

603

.

65

Hwu

P.

,

Yannelli

J.

,

Kriegler

M.

et al.

Functional and molecular characterization of tumor-infiltrating lymphocytes transduced with tumor necrosis factor-alpha cDNA for the gene therapy of cancer in humans

.

J Immunol

1993

;

150

:

4104

–

4115

.

66

Lotze

MT

,

Rubin

JT

,

Carty

S.

et al.

Gene therapy of cancer: a pilot study of IL-4-gene-modified fibroblasts admixed with autologous tumor to elicit an immune response

.

Hum Gene Ther

1994

;

5

:

41

–

55

.

67

Fakhrai

H.

,

Shawler

DL

,

Gjerset

R.

et al.

Cytokine gene therapy with interleukin 2-transduced fibroblasts: effect of IL-2 dose on anti-tumor immunity

.

Hum Gene Ther

1995

;

6

:

591

–

601

.

68

Mertelsmann

R.

,

Lindemann

A.

,

Boehm

T.

et al.

Pilot study for the evaluation of T-cell mediated tumor immunotherapy by cytokine gene transfer in patients with malignant tumors

.

J Mol Med

1995

;

73

:

205

–

206

.

69

Mackensen

A.

,

Veelken

H.

,

Lahn

M.

et al.

Amplification of tumor specific cytotoxic T-lymphocytes by immunization with autologous tumor cells and interleukin-2 gene transfected fibroblasts

.J Mol Med

1997

(in press).

70

Veelken

H.

,

Mackensen

A.

,

Lahn

M.

et al.

A phase I clinical study of autologous tumor cells plus interleukin-2-gene-transfected allogeneic fibroblasts as a vaccine in patients with cancer

.

Int J Cancer

1997

;

70

:

269

–

277

.

71

Henderson

RA

,

Nimgaonkar

MT

,

Watkins

SC

et al.

Human dendritic cells genetically engineered to expression high levels of the human epithelial tumor antigen mucin (MUC-1)

.

Cancer Res

1996

;

56

:

3763

–

3770

.